(BSX) Boston Scientific - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US1011371077
Stock: Stent, Catheter, Defibrillator, Pacemaker, Endoscope
Total Rating 37
Risk 73
Buy Signal -0.53
| Risk 5d forecast | |
|---|---|
| Volatility | 29.3% |
| Relative Tail Risk | -7.29% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.04 |
| Alpha | -41.85 |
| Character TTM | |
|---|---|
| Beta | 0.577 |
| Beta Downside | 0.817 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.02% |
| CAGR/Max DD | 0.44 |
EPS (Earnings per Share)
Revenue
Description: BSX Boston Scientific February 27, 2026
Boston Scientific (BSX) designs, manufactures and markets a broad portfolio of medical devices across two primary segments-MedSurg and Cardiovascular-serving specialties such as gastrointestinal, urology, neuromodulation, and cardiac rhythm management. Its product lineup includes endoscopic tools, ureteral stents, spinal cord stimulators, and implantable cardiac devices like the WATCHMAN FLX left-atrial appendage closure system.
In its most recent fiscal year (2023), Boston Scientific reported revenue of $11.5 billion, up roughly 10 % year-over-year, with an operating margin of 24 % and earnings per share of $4.14. The company invested $1.7 billion in R&D, reflecting a continued focus on next-generation minimally invasive technologies, and generated $2.3 billion in operating cash flow, supporting a dividend yield near 0.7 %.
Key sector drivers include an aging U.S. population that is expanding the addressable market for cardiovascular and neuro-interventional devices, accelerating adoption of outpatient and minimally invasive procedures, and favorable reimbursement trends for high-value implantable therapies. These macro-level forces underpin the growth outlook for the broader health-care equipment industry.
For a deeper dive into BSX’s valuation metrics, you might explore ValueRay’s analysis.
Headlines to watch out for
- Cardiovascular device sales drive revenue growth
- MedSurg segment expands product offerings
- Regulatory approvals impact new product launches
- Healthcare spending trends affect device demand
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 2.89b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 2.11 > 1.0 |
| NWC/Revenue: 16.71% < 20% (prev 3.11%; Δ 13.60% < -1%) |
| CFO/TA 0.10 > 3% & CFO 4.53b > Net Income 2.89b |
| Net Debt (10.37b) to EBITDA (4.91b): 2.11 < 3 |
| Current Ratio: 1.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.50b) vs 12m ago 0.38% < -2% |
| Gross Margin: 69.01% > 18% (prev 0.61%; Δ 6840 % > 0.5%) |
| Asset Turnover: 48.33% > 50% (prev 42.51%; Δ 5.83% > 0%) |
| Interest Coverage Ratio: 8.33 > 6 (EBITDA TTM 4.91b / Interest Expense TTM 354.0m) |
Altman Z'' 1.67
| A: 0.08 (Total Current Assets 8.79b - Total Current Liabilities 5.44b) / Total Assets 43.67b |
| B: 0.13 (Retained Earnings 5.57b / Total Assets 43.67b) |
| C: 0.07 (EBIT TTM 2.95b / Avg Total Assets 41.53b) |
| D: 0.26 (Book Value of Equity 4.98b / Total Liabilities 19.20b) |
| Altman-Z'' Score: 1.67 = BB |
Beneish M -3.09
| DSRI: 0.95 (Receivables 2.93b/2.56b, Revenue 20.07b/16.75b) |
| GMI: 0.89 (GM 69.01% / 61.44%) |
| AQI: 0.95 (AQ_t 0.70 / AQ_t-1 0.73) |
| SGI: 1.20 (Revenue 20.07b / 16.75b) |
| TATA: -0.04 (NI 2.89b - CFO 4.53b) / TA 43.67b) |
| Beneish M-Score: -3.09 (Cap -4..+1) = AA |
What is the price of BSX shares?
As of March 10, 2026, the stock is trading at USD 71.90 with a total of 11,650,694 shares traded.
Over the past week, the price has changed by -5.67%, over one month by -3.00%, over three months by -22.30% and over the past year by -23.62%.
Over the past week, the price has changed by -5.67%, over one month by -3.00%, over three months by -22.30% and over the past year by -23.62%.
Is BSX a buy, sell or hold?
Boston Scientific has received a consensus analysts rating of 4.59.
Therefore, it is recommended to buy BSX.
- StrongBuy: 23
- Buy: 8
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BSX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 104.2 | 45% |
| Analysts Target Price | 104.2 | 45% |
BSX Fundamental Data Overview March 10, 2026
P/E Trailing = 36.7783
P/E Forward = 20.6612
P/S = 5.2742
P/B = 4.3692
P/EG = 0.7928
Revenue TTM = 20.07b USD
EBIT TTM = 2.95b USD
EBITDA TTM = 4.91b USD
Long Term Debt = 11.14b USD (from longTermDebt, last quarter)
Short Term Debt = 389.0m USD (from shortTermDebt, last quarter)
Debt = 12.42b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.37b USD (from netDebt column, last quarter)
Enterprise Value = 116.33b USD (105.88b + Debt 12.42b - CCE 1.97b)
Interest Coverage Ratio = 8.33 (Ebit TTM 2.95b / Interest Expense TTM 354.0m)
EV/FCF = 32.09x (Enterprise Value 116.33b / FCF TTM 3.62b)
FCF Yield = 3.12% (FCF TTM 3.62b / Enterprise Value 116.33b)
FCF Margin = 18.06% (FCF TTM 3.62b / Revenue TTM 20.07b)
Net Margin = 14.40% (Net Income TTM 2.89b / Revenue TTM 20.07b)
Gross Margin = 69.01% ((Revenue TTM 20.07b - Cost of Revenue TTM 6.22b) / Revenue TTM)
Gross Margin QoQ = 74.50% (prev 69.93%)
Tobins Q-Ratio = 2.66 (Enterprise Value 116.33b / Total Assets 43.67b)
Interest Expense / Debt = 0.72% (Interest Expense 90.0m / Debt 12.42b)
Taxrate = 4.43% (31.0m / 700.0m)
NOPAT = 2.82b (EBIT 2.95b * (1 - 4.43%))
Current Ratio = 1.62 (Total Current Assets 8.79b / Total Current Liabilities 5.44b)
Debt / Equity = 0.51 (Debt 12.42b / totalStockholderEquity, last quarter 24.23b)
Debt / EBITDA = 2.11 (Net Debt 10.37b / EBITDA 4.91b)
Debt / FCF = 2.86 (Net Debt 10.37b / FCF TTM 3.62b)
Total Stockholder Equity = 23.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.96% (Net Income 2.89b / Total Assets 43.67b)
RoE = 12.53% (Net Income TTM 2.89b / Total Stockholder Equity 23.06b)
RoCE = 8.62% (EBIT 2.95b / Capital Employed (Equity 23.06b + L.T.Debt 11.14b))
RoIC = 8.19% (NOPAT 2.82b / Invested Capital 34.42b)
WACC = 7.27% (E(105.88b)/V(118.29b) * Re(8.04%) + D(12.42b)/V(118.29b) * Rd(0.72%) * (1-Tc(0.04)))
Discount Rate = 8.04% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.64%
[DCF] Terminal Value 83.68% ; FCFF base≈3.15b ; Y1≈3.89b ; Y5≈6.62b
[DCF] Fair Price = 81.40 (EV 131.17b - Net Debt 10.37b = Equity 120.79b / Shares 1.48b; r=7.27% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 98.51 | EPS CAGR: 21.12% | SUE: 1.19 | # QB: 13
Revenue Correlation: 98.82 | Revenue CAGR: 16.04% | SUE: 0.04 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.87 | Chg7d=-0.000 | Chg30d=-0.006 | Revisions Net=-3 | Analysts=25
EPS current Year (2026-12-31): EPS=3.47 | Chg7d=+0.007 | Chg30d=-0.001 | Revisions Net=-4 | Growth EPS=+13.4% | Growth Revenue=+11.1%
EPS next Year (2027-12-31): EPS=3.92 | Chg7d=+0.002 | Chg30d=-0.018 | Revisions Net=-4 | Growth EPS=+12.9% | Growth Revenue=+10.4%
[Analyst] Revisions Ratio: -0.20 (6 Up / 9 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.3% (Discount Rate 8.0% - Earnings Yield 2.7%)
[Growth] Growth Spread = +4.6% (Analyst 10.0% - Implied 5.3%)
P/E Forward = 20.6612
P/S = 5.2742
P/B = 4.3692
P/EG = 0.7928
Revenue TTM = 20.07b USD
EBIT TTM = 2.95b USD
EBITDA TTM = 4.91b USD
Long Term Debt = 11.14b USD (from longTermDebt, last quarter)
Short Term Debt = 389.0m USD (from shortTermDebt, last quarter)
Debt = 12.42b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.37b USD (from netDebt column, last quarter)
Enterprise Value = 116.33b USD (105.88b + Debt 12.42b - CCE 1.97b)
Interest Coverage Ratio = 8.33 (Ebit TTM 2.95b / Interest Expense TTM 354.0m)
EV/FCF = 32.09x (Enterprise Value 116.33b / FCF TTM 3.62b)
FCF Yield = 3.12% (FCF TTM 3.62b / Enterprise Value 116.33b)
FCF Margin = 18.06% (FCF TTM 3.62b / Revenue TTM 20.07b)
Net Margin = 14.40% (Net Income TTM 2.89b / Revenue TTM 20.07b)
Gross Margin = 69.01% ((Revenue TTM 20.07b - Cost of Revenue TTM 6.22b) / Revenue TTM)
Gross Margin QoQ = 74.50% (prev 69.93%)
Tobins Q-Ratio = 2.66 (Enterprise Value 116.33b / Total Assets 43.67b)
Interest Expense / Debt = 0.72% (Interest Expense 90.0m / Debt 12.42b)
Taxrate = 4.43% (31.0m / 700.0m)
NOPAT = 2.82b (EBIT 2.95b * (1 - 4.43%))
Current Ratio = 1.62 (Total Current Assets 8.79b / Total Current Liabilities 5.44b)
Debt / Equity = 0.51 (Debt 12.42b / totalStockholderEquity, last quarter 24.23b)
Debt / EBITDA = 2.11 (Net Debt 10.37b / EBITDA 4.91b)
Debt / FCF = 2.86 (Net Debt 10.37b / FCF TTM 3.62b)
Total Stockholder Equity = 23.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.96% (Net Income 2.89b / Total Assets 43.67b)
RoE = 12.53% (Net Income TTM 2.89b / Total Stockholder Equity 23.06b)
RoCE = 8.62% (EBIT 2.95b / Capital Employed (Equity 23.06b + L.T.Debt 11.14b))
RoIC = 8.19% (NOPAT 2.82b / Invested Capital 34.42b)
WACC = 7.27% (E(105.88b)/V(118.29b) * Re(8.04%) + D(12.42b)/V(118.29b) * Rd(0.72%) * (1-Tc(0.04)))
Discount Rate = 8.04% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.64%
[DCF] Terminal Value 83.68% ; FCFF base≈3.15b ; Y1≈3.89b ; Y5≈6.62b
[DCF] Fair Price = 81.40 (EV 131.17b - Net Debt 10.37b = Equity 120.79b / Shares 1.48b; r=7.27% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 98.51 | EPS CAGR: 21.12% | SUE: 1.19 | # QB: 13
Revenue Correlation: 98.82 | Revenue CAGR: 16.04% | SUE: 0.04 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.87 | Chg7d=-0.000 | Chg30d=-0.006 | Revisions Net=-3 | Analysts=25
EPS current Year (2026-12-31): EPS=3.47 | Chg7d=+0.007 | Chg30d=-0.001 | Revisions Net=-4 | Growth EPS=+13.4% | Growth Revenue=+11.1%
EPS next Year (2027-12-31): EPS=3.92 | Chg7d=+0.002 | Chg30d=-0.018 | Revisions Net=-4 | Growth EPS=+12.9% | Growth Revenue=+10.4%
[Analyst] Revisions Ratio: -0.20 (6 Up / 9 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.3% (Discount Rate 8.0% - Earnings Yield 2.7%)
[Growth] Growth Spread = +4.6% (Analyst 10.0% - Implied 5.3%)